Sorafenib treatment of HepG2 tumours slightly increased the expression of ΑFP, while sorafenib treatment of stem‐like tumours reduced the expression of CD133 but did not induce a significant modification of AFP or ALDH1A1. This evidence concerns the gene PROM1 and neoplasm.